Actinomycosis

Back

Background

Actinomycosis is a subacute-to-chronic bacterial infection caused by filamentous, gram-positive, non–acid-fast, anaerobic-to-microaerophilic bacteria. It is characterized by contiguous spread, suppurative and granulomatous inflammation, and formation of multiple abscesses and sinus tracts that may discharge sulfur granules. The most common clinical forms of actinomycosis are cervicofacial (ie, lumpy jaw), thoracic, and abdominal. In women, pelvic actinomycosis is possible.

For additional information on actinomycosis, see the articles Actinomycosis (dermatology focus), Actinomycosis (pediatrics focus), and Actinomycosis (ophthalmology focus).

Pathophysiology

Actinomycetes are prominent among the normal flora of the oral cavity but less prominent in the lower gastrointestinal tract and female genital tract. Because these microorganisms are not virulent, they require a break in the integrity of the mucous membranes and the presence of devitalized tissue to invade deeper body structures and to cause human illness.

Furthermore, actinomycosis is generally a polymicrobial infection, with isolates numbering as many as 5-10 bacterial species. Establishment of human infection may require the presence of such companion bacteria, which participate in the production of infection by elaborating a toxin or enzyme or by inhibiting host defenses. These companion bacteria appear to act as copathogens that enhance the relatively low invasiveness of actinomycetes. Specifically, they may be responsible for the early manifestations of actinomycosis and for treatment failures.

Once infection is established, the host mounts an intense inflammatory response (ie, suppurative, granulomatous), and fibrosis may then follow. Infection typically spreads contiguously, frequently ignoring tissue planes and invading surrounding tissues or organs. Ultimately, the infection produces draining sinus tracts. Hematogenous dissemination to distant organs may occur in any stage of actinomycosis, whereas lymphatic dissemination is unusual.

Cervicofacial actinomycosis

Cervicofacial actinomycosis is the most common type of the infection, comprising 50-70% of reported cases. This infection typically occurs following oral surgery or in patients with poor dental hygiene. Cervicofacial actinomycosis is characterized in the initial stages by soft-tissue swelling of the perimandibular area. Direct spread into the adjacent tissues occurs over time, along with development of fistulas (sinus tracts) that discharge purulent material containing granules with a yellow sulfurlike appearance (termed sulfur granules). Invasion of the cranium or the bloodstream may occur if the disease is left untreated.

Thoracic actinomycosis

Thoracic actinomycosis accounts for 15-20% of cases. Aspiration of oropharyngeal secretions containing actinomycetes is the usual mechanism of infection. Occasionally, thoracic actinomycosis results from the introduction of organisms via esophageal perforation, by direct spread from an actinomycotic process of the neck or abdomen, or via hematogenous spread from a distant lesion. Thoracic actinomycosis commonly presents as a pulmonary infiltrate or mass, which, if left untreated, can spread to involve the pleura, pericardium, and chest wall, ultimately leading to the formation of sinuses that discharge sulfur granules.

Actinomycosis of the abdomen and pelvis

Actinomycosis of the abdomen and pelvis accounts for 10-20% of reported cases. Typically, these patients have a history of recent or remote bowel surgery (eg, perforated acute appendicitis, perforated colonic diverticulitis following trauma to the abdomen) or ingestion of foreign bodies (eg, chicken or fish bones), during which actinomycetes are introduced into the deep tissues. The ileocecal region is involved most frequently, and the disease typically presents as a slowly growing tumor. Diagnosis is usually established postoperatively, following exploratory laparotomy for a suspected malignancy. Involvement of any abdominal organ, including the abdominal wall, can occur by direct spread, with eventual formation of draining sinuses. Pelvic actinomycosis most commonly ascends from the uterus in association with intrauterine contraceptive devices (IUCDs). In such cases, an IUCD has been in place for an average of 8 years.

Epidemiology

Frequency

United States

Actinomycosis is rare. During the 1970s, the reported annual incidence of actinomycosis in the Cleveland area was 1 case per 300,000 persons. Improved dental hygiene and widespread use of antibiotics for various infections have probably contributed to the declining incidence of this disease.

International

Actinomycosis occurs worldwide, with likely higher prevalence rates in areas with low socioeconomic status and poor dental hygiene.

Mortality/Morbidity

The availability of antibiotics has greatly improved the prognosis of all forms of actinomycosis. At present, cure rates are high, and neither deformity nor death is common.

Race

Actinomycosis has no racial predilection.

Sex

For unknown reasons, actinomycosis is more common in men than in women (male-to-female ratio, 3:1), with the exception of pelvic actinomycosis.

Age

Actinomycosis can affect people of all ages, but most cases are reported in young to middle-aged adults (aged 20-50 y).

Prognosis

When actinomycosis is diagnosed early and treated with appropriate antibiotic therapy, the prognosis is excellent.

The more advanced and complicated actinomycotic forms require aggressive antibiotic and surgical therapy for optimal outcome; however, deaths can occur despite such therapy.

Patient Education

Because actinomycosis is an endogenous infection, no risk of person-to-person transmission exists.

History

Cervicofacial actinomycosis

Cervicofacial actinomycosis (ie, lumpy jaw) may have the following features:

Thoracic actinomycosis

Thoracic actinomycosis may have the following features:

Abdominal actinomycosis

Abdominal actinomycosis may have the following features:

Pelvic actinomycosis

Pelvic actinomycosis may have the following features:

Physical

Cervicofacial actinomycosis

Patients with cervicofacial actinomycosis present with nodular lesion(s), usually located at the angle of the jaw. These gradually increase in size and number (ie, multiple abscesses), and ultimately form sinuses that open onto the cheek or submandibular area. Sulfur granules may be seen in the exudate.

Nodules may be tender in the initial stages are typically nontender and woody hard in the later stages.

Lymphadenopathy is typically absent.

Trismus is present if the mastication muscles are involved.

Fever is variably present.

Thoracic actinomycosis

Findings may include the following:

Abdominal actinomycosis

Findings may include the following:

Pelvic actinomycosis

Findings may include the following:

Causes

Actinomycosis is caused by filamentous, gram-positive, non–acid-fast, non–spore-forming bacteria. They belong to the order of Actinomycetales, family Actinomycetaceae, genus Actinomyces. The continued development of advanced molecular methods has led to the identification of additional Actinomyces species isolated from human material, with a total of 25 Actinomyces and Actinomyces-like organisms emerging as potential causes of infection at various body sites.[5] Members of the genera Propionibacterium, Actinobaculum, and Bifidobacterium may cause similar clinical syndromes. Actinomyces organisms grow slowly in anaerobic-to-microaerophilic conditions, forming colonies with a characteristic molar tooth appearance. The most common isolated species are Actinomyces israeli, Actinomyces gerencseriae, Actinomyces turicensis, Actinomyces radingae, and Actinomyces europaeus, followed by Actinomyces naeslundii, Actinomyces odontolyticus, Actinomyces viscosus, Actinomyces meyeri, and Propionibacterium propionicum.

In addition to these microorganisms, almost all actinomycotic lesions contain so-called companion bacteria. The most important of these bacteria is Actinobacillus actinomycetemcomitans, followed by Peptostreptococcus, Prevotella, Fusobacterium, Bacteroides, Staphylococcus, and Streptococcus species, and Enterobacteriaceae, depending on the location of actinomycotic lesions. These companion bacteria appear to magnify the low pathogenic potential of actinomycetes.

Complications

See the list below:

Laboratory Studies

CBC count

Anemia and mild leukocytosis are common.

Erythrocyte sedimentation rate and C-reactive protein

Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels are often elevated.

Chemistry

Chemistry results usually are normal, with the exception of a frequently elevated alkaline phosphatase level in hepatic actinomycosis.

Organism cultures

Because actinomycosis is difficult to diagnose based on the typical clinical features, direct identification and/or isolation of the infecting organism from a clinical specimen or from sulfur granules is necessary for definitive diagnosis in most cases.

Acceptable specimen material is obtained from draining sinuses, deep needle aspirate, or biopsy specimens; swabs, sputum, and urine specimens are unacceptable or inappropriate.

Prompt transport of the specimens to the microbiology laboratory is necessary for optimal isolation of actinomycetes, preferably in an anaerobic transport device.

A Gram-stained smear of the specimen may demonstrate the presence of beaded, branched, gram-positive filamentous rods, suggesting the diagnosis of actinomycosis.

Cultures should be placed immediately under anaerobic conditions and incubated for 48 hours or longer; the isolation and definitive identification of actinomycetes may require 2-3 weeks.

Nucleic acid probes and polymerase chain reaction (PCR) methods are being developed for more rapid and more accurate identification.

Antimicrobial susceptibility testing is not indicated in the management of actinomycosis, partly because of their predictable antibiogram.

Sulfur granules

The preliminary diagnosis of actinomycosis also can be made by examining sulfur granules. Granules should be crushed between 2 slides, stained with 1% methylene-blue solution, and examined microscopically for features characteristic of actinomycetes.

Serologic diagnosis

Current serologic tests have no role in diagnosing actinomycosis.

Papanicolaou test

The relationship between a Papanicolaou test that is positive for actinomycetelike organisms and the eventual development of pelvic actinomycosis is unclear.

The prevalence of smears positive for Actinomyces organisms in women who use IUCDs is approximately 7%.[6]

Because of the lack of sensitivity and specificity and low positive predictive value, the prognostic significance of detecting Actinomyces organisms is minimal in the absence of concomitant symptoms.[6]

Imaging Studies

Chest radiography

A chest radiograph may reveal a poorly defined mass or pneumonitis or cavitary lesion, with or without pleural involvement. Hilar adenopathy is uncommon.

The presence of a masslike lesion that extends across fissures or pleura, invades into the adjacent chest wall or thoracic vertebrae, or causes local destruction of the ribs or sternum suggests thoracic actinomycosis.

CT scanning

CT scanning (irrespective of the anatomic area of involvement) usually reveals an infiltrative mass with focal areas of decreased attenuation that enhance with contrast. This infiltrative mass tends to invade surrounding tissues. Surrounding lymphadenopathy is uncommon.

Procedures

CT scan or ultrasound-guided fine-needle aspiration and/or biopsy have been used successfully to obtain clinical material for diagnosis of actinomycosis.

Surgery (eg, thoracotomy with open lung biopsy, exploratory laparotomy) may be required for diagnostic purposes.

Histologic Findings

Actinomycosis is characterized by mixed suppurative and granulomatous inflammatory reactions, connective-tissue proliferation, and the presence of sulfur granules. The sulfur granules are nearly pathognomonic for actinomycosis, although similar findings have been reported with infections caused by Nocardia brasiliensis, Streptomyces madurae, and Staphylococcus aureus presenting as botryomycosis. The granules are approximately 0.1-1 mm in diameter and may be seen with the naked eye as yellowish particles.

Microscopically, the granules manifest a cauliflowerlike shape at low magnification; at higher magnification (X100), when the particle has been pressed between slide and cover slip, a clump of filamentous actinomycete microcolonies surrounded by polymorphonuclear neutrophils (PMNs) can be observed. Gram stain renders these microcolonies visible as gram-positive, intertwined branching filaments, with radially arranged, peripheral hyphae. Coexisting with them are the companion bacteria, which are gram-positive and gram-negative cocci and rods. The images below are representative photomicrographs.



View Image

Actinomycosis in the endometrial tissue, low-power view. Image courtesy of Paul Gibbs, MD.



View Image

Actinomycosis in the endometrial tissue, high-power view. Image courtesy of Paul Gibbs, MD.

Medical Care

In most cases of actinomycosis, antimicrobial therapy is the only treatment required, although surgery can be adjunctive in selected cases. Penicillin G is the drug of choice for treating infections caused by actinomycetes.

Parenteral antibiotics are administered initially via PICC line, with transition to oral agents.

Surgical Care

Attempt to cure actinomycosis, including extensive disease, with aggressive antimicrobial therapy alone initially. Surgical therapy may include incision and drainage of abscesses, excision of sinus tracts and recalcitrant fibrotic lesions, decompression of closed-space infections, and interventions aimed at relieving obstruction (eg, when actinomycotic lesions compress the ureter). In a case series of 23 patients with abdominal actinomycosis, approximately 50% of patients required emergency surgery for symptoms of peritonitis.[7]

Consultations

See the list below:

Diet

No specific dietary precautions are indicated in patients with actinomycosis.

Activity

Patients with actinomycosis may be active to the degree tolerated.

Prevention

Maintenance of good oral hygiene and adequate regular dental care are important.

Patients and physicians alike should be aware of the increased risk of infection associated with insertion of IUCD.

Long-Term Monitoring

Follow up on outpatient intravenous antibiotic programs and switch patients to oral antibiotic therapy. Prolonged antibiotic therapy is often required.

Use CT scanning and MRI to monitor the response to therapy.

Further Inpatient Care

Obtain imaging studies and percutaneous diagnostic studies to allow more expedient diagnosis of actinomycosis.

Place a peripherally inserted central catheter (PICC) for administration of intravenous antibiotics.

Arrange outpatient intravenous antibiotic therapy.

If penicillin therapy is failing, consider broadening the antimicrobial spectrum to cover the potentially uncultured companion bacteria.

Transfer

If a CT scanner or interventional radiology is not available, transfer to a facility with these services.

Medication Summary

High-dose penicillin administered over a prolonged period (6 months to 1 year) is the cornerstone of therapy for actinomycosis. These recommendations were developed at a time when patients with actinomycosis typically presented late in the course of illness with large lesions, often receiving intermittent antibiotic therapy. In addition, modern imaging modalities were not available to monitor therapy. Success with shorter courses of therapy (< 6 mo) has been reported, especially in cervicofacial actinomycosis.[8] Ultimately, the treatment duration should be tailored to the individual patient based on clinical and radiographic response. Patients should be monitored more closely if shorter treatment durations are considered.

The risk of actinomycetes developing penicillin resistance appears to be minimal. Lack of a clinical response to penicillin usually indicates the presence of resistant companion bacteria, which may require modification of the antibiotic regimen (ie, addition of an agent that is active against these copathogens).

Antibiotics that possess no activity against Actinomyces species include metronidazole, aminoglycosides, aztreonam, co-trimoxazole (TMP-SMX), penicillinase-resistant penicillins (eg, methicillin, nafcillin, oxacillin, cloxacillin), and cephalexin. The data concerning the fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) are limited; however, treatment success has been cited in case reports.[9, 10]

Penicillin G (Pfizerpen, Bicillin)

Clinical Context:  DOC for treatment of actinomycosis. Interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms.

Penicillin VK (Pen-Vee K, V-Cillin-K)

Clinical Context:  DOC for treatment of actinomycosis. Interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms.

Doxycycline (Bio-Tab, Doryx, Vibramycin)

Clinical Context:  For nonpregnant patients with penicillin allergy. Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Clindamycin (Cleocin)

Clinical Context:  Alternative in patients allergic to penicillin. Lincosamide agent that inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Drawback is lack of coverage against some companion bacteria.

Amoxicillin/clavulanic acid (Augmentin)

Clinical Context:  Drug combination that can be used alone in mild to moderately severe cases of actinomycosis; covers both pathogenic actinomycetes and companion bacteria, which frequently are resistant to penicillin.

Ceftriaxone (Rocephin)

Clinical Context:  Covers both pathogenic actinomycetes and companion bacteria, which frequently are resistant to penicillin. Useful in moderately severe to severe forms of cervicofacial and thoracic actinomycosis. Third-generation cephalosporin with broad-spectrum, gram-negative activity; lower efficacy against gram-positive organisms. Arrests bacterial growth by binding to penicillin-binding proteins.

Imipenem/cilastatin (Primaxin)

Clinical Context:  Covers both pathogenic actinomycetes and companion bacteria, which frequently are resistant to penicillin. Useful in moderately severe to severe forms of abdominal and pelvic actinomycosis.

Class Summary

Therapy must cover all likely pathogens in the context of this clinical setting.

What is actinomycosis?What is the pathophysiology of actinomycosis?What is the pathophysiology of cervicofacial actinomycosis?What is the pathophysiology of thoracic actinomycosis?What is the pathophysiology of actinomycosis of the abdomen and pelvis?What is the prevalence of actinomycosis in the US?What is the global prevalence of actinomycosis?What is the mortality and morbidity associated with actinomycosis?What is the racial predilection of actinomycosis?What are the sexual predilections of actinomycosis?Which patient groups have the highest prevalence of actinomycosis?What is the prognosis of actinomycosis?What is the risk of person-to-person transmission of actinomycosis?Which clinical history findings are characteristic of thoracic actinomycosis?Which clinical history findings are characteristic of abdominal actinomycosis?Which clinical history findings are characteristic of pelvic actinomycosis?Which clinical history findings are characteristic of cervicofacial actinomycosis?Which physical findings are characteristic of cervicofacial actinomycosis?Which physical findings are characteristic of thoracic actinomycosis?Which physical findings are characteristic of abdominal actinomycosis?Which physical findings are characteristic of pelvic actinomycosis?What causes actinomycosis?What are complications of actinomycosis?What are the differential diagnoses for Actinomycosis?Which findings on CBC count suggest actinomycosis?Which findings of the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels suggests actinomycosis?Which chemistry results suggest actinomycosis?What is the role of organism cultures in the diagnosis of actinomycosis?What is the role of sulfur granules in the diagnosis of actinomycosis?What is the role of serologic testing in the diagnosis of actinomycosis?What is the role of a Papanicolaou test in the diagnosis of actinomycosis?What is the role of chest radiography in the diagnosis of actinomycosis?What is the role of CT scanning in the diagnosis of actinomycosis?What is the role of invasive procedures in the diagnosis of actinomycosis?Which histologic findings are characteristic of actinomycosis?How is actinomycosis treated?What is the role of surgery in the treatment of actinomycosis?Which specialist consultations may be beneficial to patients with actinomycosis?Which dietary modifications are used in the treatment of actinomycosis?Which activity modifications are used in the treatment of actinomycosis?How is actinomycosis prevented?What is included in long-term monitoring of actinomycosis?What is included in inpatient care for actinomycosis?When is patient transfer indicated for the treatment of actinomycosis?What is the role of medications in the treatment of actinomycosis?Which medications in the drug class Antibiotics are used in the treatment of Actinomycosis?

Author

Jason F Okulicz, MD, FACP, FIDSA, Director, HIV Medical Evaluation Unit, Infectious Disease Service, San Antonio Military Medical Center; Associate Professor of Medicine, F Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences; Clinical Associate Professor of Medicine, University of Texas Health Science Center at San Antonio; Adjunct Clinical Instructor, Feik School of Pharmacy, University of the Incarnate Word

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Gilead Sciences.

Coauthor(s)

Hari Polenakovik, MD, FACP, FIDSA, Professor of Medicine, Wright State University, Boonshoft School of Medicine

Disclosure: Nothing to disclose.

Sylvia Polenakovik, MD, Internist, Department of Internal Medicine, Sycamore Hospital; Internist, Miami Valley Hospitalist Group, MVH; Clinical Instructor, Wright State University, Boonshoft School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Joseph F John, Jr, MD, FACP, FIDSA, FSHEA, Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina College of Medicine; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Disclosure: Nothing to disclose.

Additional Contributors

Daniel R Lucey, MD, MPH, MD, MPH,

Disclosure: Nothing to disclose.

References

  1. Hall V. Actinomyces--gathering evidence of human colonization and infection. Anaerobe. 2008 Feb. 14(1):1-7. [View Abstract]
  2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004 May. 62(5):527-34. [View Abstract]
  3. Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc. 2005 Dec. 136(12):1669-74. [View Abstract]
  4. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006 Mar. 35(3):155-60. [View Abstract]
  5. Könönen E, Wade WG. Actinomyces and related organisms in human infections. Clin Microbiol Rev. 2015 Apr. 28 (2):419-42. [View Abstract]
  6. Westhoff C. IUDs and colonization or infection with Actinomyces. Contraception. 2007 Jun. 75(6 Suppl):S48-50. [View Abstract]
  7. Sung HY, Lee IS, Kim SI, Jung SE, Kim SW, Kim SY. Clinical Features of Abdominal Actinomycosis: A 15-year Experience of A Single Institute. J Korean Med Sci. 2011 Jul. 26(7):932-7. [View Abstract]
  8. Sudhakar SS, Ross JJ. Short-term treatment of actinomycosis: two cases and a review. Clin Infect Dis. 2004 Feb 1. 38(3):444-7. [View Abstract]
  9. Macfarlane DJ, Tucker LG, Kemp RJ. Treatment of recalcitrant actinomycosis with ciprofloxacin. J Infect. 1993 Sep. 27(2):177-80. [View Abstract]
  10. Ferreira Dde F, Amado J, Neves S, Taveira N, Carvalho A, Nogueira R. Treatment of pulmonary actinomycosis with levofloxacin. J Bras Pneumol. 2008 Apr. 34(4):245-8. [View Abstract]
  11. Apotheloz C, Regamey C. Disseminated infection due to Actinomyces meyeri: case report and review. Clin Infect Dis. 1996 Apr. 22(4):621-5. [View Abstract]
  12. Arend SM, Oosterhof H, van Dissel JT. Actinomyces and the intrauterine device. Arch Intern Med. 1998 Jun 8. 158(11):1270. [View Abstract]
  13. Belmont MJ, Behar PM, Wax MK. Atypical presentations of actinomycosis. Head Neck. 1999 May. 21(3):264-8. [View Abstract]
  14. Brown JR. Human actinomycosis. A study of 181 subjects. Hum Pathol. 1973 Sep. 4(3):319-30. [View Abstract]
  15. Cayley J, Fotherby K, Guillebaud J, et al. Recommendations for clinical practice: actinomyces like organisms and intrauterine contraceptives. The Clinical and Scientific Committee. Br J Fam Plann. 1998 Jan. 23(4):137-8. [View Abstract]
  16. Chaudhry SI, Greenspan JS. Actinomycosis in HIV infection: a review of a rare complication. Int J STD AIDS. 2000 Jun. 11(6):349-55. [View Abstract]
  17. Choi J, Koh WJ, Kim TS, et al. Optimal duration of IV and oral antibiotics in the treatment of thoracic actinomycosis. Chest. 2005 Oct. 128(4):2211-7. [View Abstract]
  18. Chouabe S, Perdu D, Deslee G, et al. Endobronchial actinomycosis associated with foreign body: four cases and a review of the literature. Chest. 2002 Jun. 121(6):2069-72. [View Abstract]
  19. Cintron JR, Del Pino A, Duarte B, Wood D. Abdominal actinomycosis. Dis Colon Rectum. 1996 Jan. 39(1):105-8. [View Abstract]
  20. Clarridge JE, Zhang Q. Genotypic diversity of clinical Actinomyces species: phenotype, source, and disease correlation among genospecies. J Clin Microbiol. 2002 Sep. 40(9):3442-8. [View Abstract]
  21. Colmegna I, Rodriguez-Barradas M, Rauch R, Clarridge J, Young EJ. Disseminated Actinomyces meyeri infection resembling lung cancer with brain metastases. Am J Med Sci. 2003 Sep. 326(3):152-5. [View Abstract]
  22. Curi MM, Dib LL, Kowalski LP, et al. Opportunistic actinomycosis in osteoradionecrosis of the jaws in patients affected by head and neck cancer: incidence and clinical significance. Oral Oncol. 2000 May. 36(3):294-9. [View Abstract]
  23. de Montpreville VT, Nashashibi N, Dulmet EM. Actinomycosis and other bronchopulmonary infections with bacterial granules. Ann Diagn Pathol. 1999 Apr. 3(2):67-74. [View Abstract]
  24. Endo S, Murayama F, Yamaguchi T, et al. Surgical considerations for pulmonary actinomycosis. Ann Thorac Surg. 2002 Jul. 74(1):185-90. [View Abstract]
  25. Felekouras E, Menenakos C, Griniatsos J, et al. Liver resection in cases of isolated hepatic actinomycosis: case report and review of the literature. Scand J Infect Dis. 2004. 36(6-7):535-8. [View Abstract]
  26. Fife TD, Finegold SM, Grennan T. Pericardial actinomycosis: case report and review. Rev Infect Dis. 1991 Jan-Feb. 13(1):120-6. [View Abstract]
  27. Göçmen G, Varol A, Göker K, Basa S. Actinomycosis: report of a case with a persistent extraoral sinus tract. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Dec. 112(6):e121-3. [View Abstract]
  28. Hamid D, Baldauf JJ, Cuenin C, Ritter J. Treatment strategy for pelvic actinomycosis: case report and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2000 Apr. 89(2):197-200. [View Abstract]
  29. Hansen T, Kunkel M, Kirkpatrick CJ, Weber A. Actinomyces in infected osteoradionecrosis--underestimated?. Hum Pathol. 2006 Jan. 37(1):61-7. [View Abstract]
  30. Hsieh MJ, Liu HP, Chang JP, Chang CH. Thoracic actinomycosis. Chest. 1993 Aug. 104(2):366-70. [View Abstract]
  31. Huang KL, Beutler SM, Wang C. Endocarditis due to Actinomyces meyeri. Clin Infect Dis. 1998 Oct. 27(4):909-10. [View Abstract]
  32. Kim JC, Ahn BY, Kim HC, et al. Efficiency of combined colonoscopy and computed tomography for diagnosis of colonic actinomycosis: a retrospective evaluation of eight consecutive patients. Int J Colorectal Dis. 2000 Aug. 15(4):236-42. [View Abstract]
  33. Kim TS, Han J, Koh WJ, et al. Thoracic Actinomycosis: CT Features with Histopathologic Correlation. AJR Am J Roentgenol. 2006 Jan. 186(1):225-31. [View Abstract]
  34. Kuijper EJ, Wiggerts HO, Jonker GJ, et al. Disseminated actinomycosis due to Actinomyces meyeri and Actinobacillus actinomycetemcomitans. Scand J Infect Dis. 1992. 24(5):667-72. [View Abstract]
  35. Lequerre T, Nouvellon M, Kraznowska K, et al. Septic arthritis due to Actinomyces naeslundii: report of a case. Joint Bone Spine. 2002 Oct. 69(5):499-501. [View Abstract]
  36. Lippes J. Pelvic actinomycosis: a review and preliminary look at prevalence. Am J Obstet Gynecol. 1999 Feb. 180(2 Pt 1):265-9. [View Abstract]
  37. Litwin KA, Jadbabaie F, Villanueva M. Case of pleuropericardial disease caused by Actinomyces odontolyticus that resulted in cardiac tamponade. Clin Infect Dis. 1999 Jul. 29(1):219-20. [View Abstract]
  38. Mabeza GF, Macfarlane J. Pulmonary actinomycosis. Eur Respir J. 2003 Mar. 21(3):545-51. [View Abstract]
  39. Macfarlane DJ, Tucker LG, Kemp RJ. Treatment of recalcitrant actinomycosis with ciprofloxacin. J Infect. 1993 Sep. 27(2):177-80. [View Abstract]
  40. Oostman O, Smego RA. Cervicofacial Actinomycosis: Diagnosis and Management. Curr Infect Dis Rep. 2005 May. 7(3):170-174. [View Abstract]
  41. Pulverer G, Schutt-Gerowitt H, Schaal KP. Human cervicofacial actinomycoses: microbiological data for 1997 cases. Clin Infect Dis. 2003 Aug 15. 37(4):490-7. [View Abstract]
  42. Reddy I, Ferguson DA Jr, Sarubbi FA. Endocarditis due to Actinomyces pyogenes. Clin Infect Dis. 1997 Dec. 25(6):1476-7. [View Abstract]
  43. Rothschild B, Naples V, Barbian L. Bone manifestations of actinomycosis. Ann Diagn Pathol. 2006 Feb. 10(1):24-27. [View Abstract]
  44. Sabbe LJ, Van De Merwe D, Schouls L, et al. Clinical spectrum of infections due to the newly described Actinomyces species A. turicensis, A. radingae, and A. europaeus. J Clin Microbiol. 1999 Jan. 37(1):8-13. [View Abstract]
  45. Scarano FJ, Ruddat MS, Robinson A. Actinomyces viscosus postoperative endophthalmitis. Diagn Microbiol Infect Dis. 1999 Jun. 34(2):115-7. [View Abstract]
  46. Schaal KP, Lee HJ. Actinomycete infections in humans--a review. Gene. 1992 Jun 15. 115(1-2):201-11. [View Abstract]
  47. Schaal KP, Pape W. Special methodological problems in antibiotic susceptibility testing of fermentative actinomycetes. Infection. 1980. 8 Suppl 2:S176-82. [View Abstract]
  48. Sharma M, Briski LE, Khatib R. Hepatic actinomycosis: an overview of salient features and outcome of therapy. Scand J Infect Dis. 2002. 34(5):386-91. [View Abstract]
  49. Smego RA Jr, Foglia G. Actinomycosis. Clin Infect Dis. 1998 Jun. 26(6):1255-61; quiz 1262-3. [View Abstract]
  50. Smith AJ, Hall V, Thakker B, Gemmell CG. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents. J Antimicrob Chemother. 2005 Aug. 56(2):407-9. [View Abstract]
  51. Soria-Aledo V, Flores-Pastor B, Carrasco-Prats M, et al. Abdominopelvic actinomycosis: a serious complication in intrauterine device users. Acta Obstet Gynecol Scand. 2004 Sep. 83(9):863-5. [View Abstract]
  52. Wagenlehner FM, Mohren B, Naber KG, Mannl HF. Abdominal actinomycosis. Clin Microbiol Infect. 2003 Aug. 9(8):881-5. [View Abstract]
  53. Warren NG. Actinomycosis, nocardiosis, and actinomycetoma. Dermatol Clin. 1996 Jan. 14(1):85-95. [View Abstract]
  54. Weese WC, Smith IM. A study of 57 cases of actinomycosis over a 36-year period. A diagnostic 'failure' with good prognosis after treatment. Arch Intern Med. 1975 Dec. 135(12):1562-8. [View Abstract]
  55. Wust J, Steiger U, Vuong H, Zbinden R. Infection of a hip prosthesis by Actinomyces naeslundii. J Clin Microbiol. 2000 Feb. 38(2):929-30. [View Abstract]
  56. Xia T, Baumgartner JC. Occurrence of Actinomyces in infections of endodontic origin. J Endod. 2003 Sep. 29(9):549-52. [View Abstract]
  57. Yung BC, Cheng JC, Chan TT, et al. Aggressive thoracic actinomycosis complicated by vertebral osteomyelitis and epidural abscess leading to spinal cord compression. Spine. 2000 Mar 15. 25(6):745-8. [View Abstract]

Actinomycosis in the endometrial tissue, low-power view. Image courtesy of Paul Gibbs, MD.

Actinomycosis in the endometrial tissue, high-power view. Image courtesy of Paul Gibbs, MD.

Actinomycosis in the endometrial tissue, low-power view. Image courtesy of Paul Gibbs, MD.

Actinomycosis in the endometrial tissue, high-power view. Image courtesy of Paul Gibbs, MD.